Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- For 16th Consecutive Year, Pancreatic Cancer Action Network Awarded Four-Star Rating From Charity Navigatoron June 24, 2020 at 5:26 am
For 16th Consecutive Year, Pancreatic Cancer Action Network Awarded Four-Star Rating From Charity NavigatorPR NewswireMANHATTAN BEACH, Calif., June 24, 2020Fewer Than One Percent of All Rated ...
- PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trialon June 23, 2020 at 4:00 am
Set forth below is a list of the major items to be finalized by PharmaCyte and its consultants before PharmaCyte submits the IND to the FDA. Study Reports and related information of prior clinical ...
- Couple's Engagement Encourages Single Mother Battling Pancreatic Canceron June 22, 2020 at 5:06 pm
COVID-19 concerns couldn’t keep a local couple from starting a new chapter this weekend, and their socially-distanced engagement celebration may have meant even more to one Minnesota mother, Frank ...
- AACR: Attacking pancreatic cancer by thwarting its survival strategieson June 22, 2020 at 6:35 am
At this week’s virtual meeting of the American Association for Cancer Research (AACR), several research groups are presenting new therapeutic tactics aimed at interrupting survival pathways in ...
- 4 Things About Pancreatic Cancer Diagnostic Market That Will Change Coming Decadeon June 19, 2020 at 10:26 am
Click to get Global Pancreatic Cancer Diagnostic Market Research Sample PDF Copy Here @ According to the American Cancer Society, around 3 percent of all cancers in the United States are pancreatic ...
- Pancreatic Cancer Therapeutics Market 2020 Analysis report with Cross-Channel, Opportunities, Upturn Growth by 2026on June 19, 2020 at 3:51 am
The report provides rational insights along with historical and forecast data to aid in better understanding of ...
- 5 for Good: Local families advocate for support in fighting pancreatic canceron June 18, 2020 at 4:00 pm
"She's been so positive and so inspiring and so strong,” said Ivy Watts, talking about her mother who was diagnosed with pancreatic cancer in September. Watts said it was caught in stage two. "The ...
- July 19 Naperville Pancreatic Cancer Walk: VIRTUAL & MATCHED!on June 18, 2020 at 1:00 pm
Cancer hasn't stopped, so neither have we. The July 19, 2020 Naperville Walk to support Pancreatic Cancer Research will be virtual, and MATCHED! Right now, all funds raised online for the ...
- Researchers find a new therapeutic target in pancreatic canceron June 18, 2020 at 8:02 am
The development of pancreatic cancer is driven by co-existing mutations in an oncogene involved in controlling cell growth, called KRAS, and in a tumor suppressor gene, called p53. But how these ...
- Ipsen's Onivyde Fast Track'd for combination treatment for pancreatic canceron June 17, 2020 at 3:17 am
The FDA has granted Fast Track designation for Ipsen's (OTCPK:IPSEY) investigational use of liposomal irinotecan (ONIVYDE) in combination with 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin ( ...
via Bing News